Expression and clinical significance of doublecortin (DCX) in pituitary adenoma.
To date, no studies have investigated the expression of Doublecortin (DCX) in pituitary adenomas or evaluated the clinical value of DCX in the diagnosis of pituitary adenomas. This study aims to determine the expression levels of DCX in pituitary adenomas and to investigate its role in the staging of this condition. Forty-six patients with pituitary adenomas were recruited. The expression of DCX in tumor sections from pituitary adenomas was determined using immunohistochemistry and quantitative real-time polymerase chain reaction. Tumors were classified as either invasive or non-invasive on the basis of clinical stage and using the Knosp grading system. Differences in the expression of DCX and its association with clinical characteristics were investigated. The potential of the measurement of DCX levels for distinguishing between invasive and non-invasive tumors was estimated using receiver operating characteristic (ROC) analysis. Expression of DCX were correlated with Knosp grade. No significant association was observed between DCX level and the clinical stage of the tumors. The expression of DCX was higher in tumors with Knosp 3 and lowest in Knosp 1, at both the mRNA and protein levels. Using DCX as a biomarker for the prediction of tumor invasiveness in pituitary adenoma patients, the area under the ROC curve was 0.829 (95% confidence interval, 0.6-28.1), which is higher than that obtained using Knosp grade. The expression of DCX is related to the Knosp grade of pituitary adenoma. DCX levels can be used as a biomarker for tumor invasiveness prediction in pituitary adenoma patients.